Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.73 |
| ▸ | MMP9 | P14780 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7665919 | 1.00 | MMP2 (0.73) | MMP2MMP9LMNAADAMTS4MEN1 | |
| SCHEMBL7671437 | 0.90 | MMP9 (0.59) | MMP2MMP9LMNAADAMTS4MEN1 | |
| SCHEMBL7667739 | 0.90 | MMP9 (0.59) | MMP2MMP9LMNAADAMTS4MEN1 | |
| SCHEMBL7669662 | 0.89 | MMP9 (0.62) | MMP2MMP9LMNAMEN1KMT2A | |
| SCHEMBL14419201 | 0.86 | MMP9 (0.56) | MMP2MMP9ADAMTS4 | |
| SCHEMBL7667857 | 0.85 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP14 | |
| SCHEMBL6424211 | 0.85 | MMP2 (1.00) | MMP2MMP9ADAMTS4MMP14 | |
| SCHEMBL7673536 | 0.84 | MMP9 (0.57) | MMP2MMP9LMNAMEN1KMT2A | |
| SCHEMBL7665170 | 0.84 | MMP9 (0.57) | MMP2MMP9LMNAMEN1KMT2A | |
| SCHEMBL1655876 | 0.84 | MMP2 (0.52) | MMP2MMP9ADAMTS4MMP14HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |